Medistem Laboratories, Inc.

Stem cell company licenses intellectual property to Institute for Cellular Medicine

Published in Lab Law Weekly, March 10th, 2006

Medistem Laboratories, Inc. (MDSM, S2U) announced that it has executed a technology licensing and royalty agreement with the Institute for Cellular Medicine (ICM) which allows ICM to perform clinical programs to further develop Medistem's stem cell therapies and treat patients on a fee-for-service basis at ICM's facility in San Jose, Costa Rica.

The licensing agreement stipulates that ICM will pay royalties to Medistem for the use of Medistem's technologies. In addition to royalties, all intellectual property developed by ICM through their research and clinical treatment programs will be the property of Medistem.

ICM has acquired the lease for their...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2006-03-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry